Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Heidelberg Pharma AG's annualized net income for the quarter that ended in May. 2026 was €3.45 Mil. Heidelberg Pharma AG's average shareholder tangible equity for the quarter that ended in May. 2026 was €0.00 Mil. Therefore, Heidelberg Pharma AG's annualized Return-on-Tangible-Equity for the quarter that ended in May. 2026 was N/A%.
The historical rank and industry rank for Heidelberg Pharma AG's Return-on-Tangible-Equity or its related term are showing as below:
XTER:HPHA's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.15 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Heidelberg Pharma AG (XTER:HPHA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Heidelberg Pharma AG Return-on-Tangible-Equity Related Terms
Heidelberg Pharma AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG Return-on-Tangible-Equity Chart
XTER:HPHA vs VRTX, REGN, MRNA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (May. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Heidelberg Pharma AG (XTER:HPHA) has a Return-on-Tangible-Equity of % as of May. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Heidelberg Pharma AG and its competitors. According to the industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 1204 companies in the Biotechnology industry.
Is Heidelberg Pharma AG's Return-on-Tangible-Equity too high?
Heidelberg Pharma AG's current Return-on-Tangible-Equity is %. Based on the distribution chart, Heidelberg Pharma AG ranks #999999 out of 1204 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 1204 companies for Return-on-Tangible-Equity. This places Heidelberg Pharma AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Return-on-Tangible-Equity is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Fairly Valued. The stock's GF Value™ is €2.55, compared to a current price of €2.49 — trading 2.4% below its estimated fair value. The current Return-on-Tangible-Equity is %. Heidelberg Pharma AG's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current Return-on-Tangible-Equity is % as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.49 is trading 2.4% below its estimated GF Value™ of €2.55.
GuruFocus considers Heidelberg Pharma AG to be Fairly Valued.
Key valuation signals for XTER:HPHA:
Return-on-Tangible-Equity: %
GF Value™: €2.55 vs. price of €2.49 (2.4% below fair value)
No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a German biopharmaceutical company focused on oncology, specializing in antibody drug conjugates (ADCs) that combine the targeting specificity of antibodies with cytotoxic payloads to selectively attack cancer cells. Its core platform is ATAC (Antibody Targeted Amanitin Conjugates), based on amanitin, a toxin derived from the death cap mushroom, which acts through a distinct mechanism intended to overcome tumor resistance. The company uses this technology both to develop its own proprietary ADC candidates and in research collaborations and licensing arrangements with pharmaceutical partners. Heidelberg Pharma also provides ADC research and manufacturing services. Its operations span drug discovery, preclinical and clinical development, and production, with activities centered in Germany and partnerships extending internationally. Revenue derives from collaboration and licensing agreements, research funding, and service fees rather than from marketed products.
51GF Score
Get the complete analysis for XTER:HPHA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HPHA has been successfully added to your 
